title: Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group.
abstract: OBJECTIVE
  To investigate a possible dose-effect relationship with two dosages of oral slow-release mesalazine in patients with quiescent ulcerative colitis.
  
  
  METHODS
  One hundred and sixty-nine patients with ulcerative colitis in remission were treated with either 1.5 or 3.0 g/day mesalazine for 1 year or until relapse into active colitis.
  
  
  RESULTS
  Fewer of the 3.0 g dose group relapsed than of the 1.5 g dose group (33 compared with 46%). This difference failed to reach statistical significance (P = 0.057). A significant relationship between age and relapse rate was established. No dose-related adverse events were found. Three serious drug-related adverse events were, however, reported. All of the serious adverse reactions resolved after the medication was discontinued.
  
  
  CONCLUSIONS
  There is a trend for high doses of oral mesalazine to be more effective in prevention of relapse of ulcerative colitis. These higher doses are not associated with a higher incidence of adverse reactions.
authors.affiliation: Department of Gastroenterology, Academic Medical Centre, Amsterdam, Netherlands.
authors.forename: P
authors.initials: P
authors.lastname: Fockens
authors.forename: C J
authors.initials: CJ
authors.lastname: Mulder
authors.forename: G N
authors.initials: GN
authors.lastname: Tytgat
authors.forename: P
authors.initials: P
authors.lastname: Blok
authors.forename: J
authors.initials: J
authors.lastname: Ferwerda
authors.forename: S G
authors.initials: SG
authors.lastname: Meuwissen
authors.forename: H A
authors.initials: HA
authors.lastname: Tuynman
authors.forename: W
authors.initials: W
authors.lastname: Dekker
authors.forename: K
authors.initials: K
authors.lastname: Gasthuis
authors.forename: P A
authors.initials: PA
authors.lastname: van Hees
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000636:Aminosalicylic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D019804:Mesalamine; D008875:Middle Aged; D012812:Sigmoidoscopy; D013997:Time Factors
chemical_list: D000636:Aminosalicylic Acids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D003692:Delayed-Action Preparations; D019804:Mesalamine